MYDA Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.52M Buy
+16,000
New +$2.53M 0.28% 74
2023
Q4
– Sell
-28,000
Closed -$2.04M – 129
2023
Q3
$2.04M Buy
+28,000
New +$2.24M 0.66% 41
2022
Q3
– Sell
-41,000
Closed -$3.04M – 209
2022
Q2
$3.04M Buy
+41,000
New +$3.08M 0.85% 24
2022
Q1
– Sell
-34,000
Closed -$3.81M – 265
2021
Q4
$3.81M Buy
34,000
+22,000
+183% +$2.65M 1.02% 28
2021
Q3
$1.51M Buy
+12,000
New +$1.55M 0.42% 62
2021
Q2
– Sell
-10,000
Closed -$1.36M – 347
2021
Q1
$1.36M Buy
+10,000
New +$1.5M 0.38% 84
2020
Q1
– Sell
-18,000
Closed -$1.71M – 173
2019
Q4
$1.71M Buy
+18,000
New +$1.56M 0.75% 39
2019
Q1
– Sell
-10,000
Closed -$718K – 142
2018
Q4
$718K Buy
+10,000
New +$806K 1.23% 24
2018
Q1
– Sell
-23,000
Closed -$1.95M – 184
2017
Q4
$1.95M Buy
+23,000
New +$1.93M 0.87% 27

Other funds holding XBI

MYDA Advisors's XBI Position: Q3 2026 in Review

MYDA Advisors opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2026: 16,000 shares worth $2.52M. The stake represents 0.28% of the portfolio and ranks #74 among its holdings. This is a return to the name: MYDA Advisors previously reported a position in XBI as recently as Q3 2023.

MYDA Advisors first reported a position in XBI in Q4 2017 and has held it in 9 quarters since. The position peaked at $3.81M in Q4 2021. 961 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • MYDA Advisors held 16,000 shares of State Street SPDR S&P Biotech ETF worth $2.52M as of Q3 2026.
  • State Street SPDR S&P Biotech ETF was a new MYDA Advisors position in Q3 2026.
  • State Street SPDR S&P Biotech ETF made up 0.28% of MYDA Advisors's portfolio in Q3 2026, its #74 holding.
  • MYDA Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 9 quarters since.
  • MYDA Advisors's State Street SPDR S&P Biotech ETF position peaked at $3.81M in Q4 2021.
  • 961 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on MYDA Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.